Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center

被引:2
|
作者
Gren, Lisa H. [1 ]
Lamerato, Lois E. [2 ]
Wright, Patrick [3 ]
Marcus, Pamela M. [4 ]
机构
[1] Univ Utah, Dept Family & Prevent Med, Salt Lake City, UT 84112 USA
[2] Henry Ford Hlth Syst, Detroit, MI USA
[3] Informat Management Serv Inc, Rockville, MD USA
[4] Natl Canc Inst, Div Canc Control & Populat Sci, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA
关键词
Cancer; lung; screening; self-report; validation; x-ray;
D O I
10.2174/1574887110666150731145929
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It is imperative to measure the degree of contamination throughout the course of randomized controlled trials, as contamination, the receipt of the intervention arm regimen by control arm participants, can affect trial power. In the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, contamination was estimated through use of the self-administered Health Status Questionnaire (HSQ) annually to a randomly-selected subset of control arm participants. We examined agreement of self-report of chest x-ray on the HSQ with clinic records at one of the 10 PLCO screening centers (Henry Ford Health System, or HFHS). We focus on HFHS participants covered by the Health Alliance Plan (HAP), a managed health care insurance plan owned and operated by HFHS, because claims for care received both at HFHS and other facilities are available in HFHS databases for HAP enrollees. We examined agreement for the six years prior to HSQ completion, with HFHS clinic records considered to be the gold standard. For those who had complete HAP coverage during the six years, percent agreement was 0.69, sensitivity was 0.84, and positive predictive value was 0.76. Specificity and negative predicted value were low, however (0.28 and 0.38, respectively), and Cohen's kappa was 0.13. For groups with incomplete or no HAP coverage, and when timing of exam was considered, performance measures typically became lower, in some instances below 0.20. These data suggest that self-report of chest x-ray screening may not be accurate, although high prevalence of chest x-ray may make performance measures less interpretable.
引用
收藏
页码:194 / 199
页数:6
相关论文
共 50 条
  • [31] Is the chest X-ray an appropriate screening exam for ER patients with AMS?
    Birkemeier K.L.
    Nipper M.L.
    Williams J.M.
    [J]. Emergency Radiology, 2008, 15 (6) : 421 - 425
  • [32] Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Pinsk, Paul F.
    Black, Amanda
    Daugherty, Sarah E.
    Hoover, Robert
    Parnes, Howard
    Smith, Zachary L.
    Eggener, Scott
    Andriole, Gerald L.
    Berndt, Sonja, I
    [J]. CANCER, 2019, 125 (17) : 2965 - 2974
  • [33] Dietary consumption of tea and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Thomas, Robert
    Greef, Basma
    McConnachie, Alex
    Stanley, Bethany
    Williams, Madeleine
    [J]. BRITISH JOURNAL OF NUTRITION, 2022, 128 (04) : 653 - 658
  • [34] Dietary intake of phytoestrogens and the risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Reger, Michael
    Zollinger, Terrell
    Liu, Ziyue
    Jones, Josette
    Zhang, Jianjun
    [J]. CANCER RESEARCH, 2015, 75
  • [35] Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
    Huang, Jiaqi
    Mondul, Alison M.
    Weinstein, Stephanie J.
    Koutros, Stella
    Derkach, Andriy
    Karoly, Edward
    Sampson, Joshua N.
    Moore, Steven C.
    Berndt, Sonja I.
    Albanes, Demetrius
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (09) : 1087 - 1095
  • [36] Image quality assurance in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial network of the National Lung Screening Trial
    Moore, SM
    Gierada, DS
    Clark, KW
    Blaine, J
    [J]. JOURNAL OF DIGITAL IMAGING, 2005, 18 (03) : 242 - 250
  • [37] Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
    Jiaqi Huang
    Alison M Mondul
    Stephanie J Weinstein
    Stella Koutros
    Andriy Derkach
    Edward Karoly
    Joshua N Sampson
    Steven C Moore
    Sonja I Berndt
    Demetrius Albanes
    [J]. British Journal of Cancer, 2016, 115 : 1087 - 1095
  • [38] Image Quality Assurance in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Network of the National Lung Screening Trial
    Stephen M. Moore
    David S. Gierada
    Kenneth W. Clark
    G. James Blaine
    [J]. Journal of Digital Imaging, 2005, 18 : 242 - 250
  • [39] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
    Andriole, GL
    Levin, DL
    Crawford, ED
    Gelmann, ER
    Pinsky, PF
    Chia, D
    Kramer, BS
    Reding, D
    Church, TR
    Grubb, RL
    Izmirlian, G
    Ragard, LR
    Clapp, JD
    Prorok, PC
    Gohagan, JK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) : 433 - 438
  • [40] Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    Buys, Saundra S.
    Partridge, Edward
    Black, Amanda
    Johnson, Christine C.
    Lamerato, Lois
    Isaacs, Claudine
    Reding, Douglas J.
    Greenlee, Robert T.
    Yokochi, Lance A.
    Kessel, Bruce
    Crawford, E. David
    Church, Timothy R.
    Andriole, Gerald L.
    Weissfeld, Joel L.
    Fouad, Mona N.
    Chia, David
    O'Brien, Barbara
    Ragard, Lawrence R.
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hartge, Patricia
    Pinsky, Paul F.
    Zhu, Claire S.
    Izmirlian, Grant
    Kramer, Barnett S.
    Miller, Anthony B.
    Xu, Jian-Lun
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2295 - 2303